Theratechnologies names Huss president, CEO

> Theratechnologies has named John-Michel Huss as president and CEO. Theratechnologies release

> During its first meeting, the board of directors of Pierre Fabre appointed Olivier Bohuon as the company's CEO. Pierre Fabre release

> Bionor Pharma has announced that Henrik Lund will take over the position of CEO from Trond Syvertsen. Bionor release

> Synexus has tapped Christophe Berthoux to become chief executive. Synexus release

> Oncothyreon has named Julie Eastland as CFO and VP, corporate development, effective Sept. 7. Oncothyreon release

> David Cohen is set to become COO of Millennium Laboratories. Millennium release

> King Pharmaceuticals has tapped Jeffrey Bailey to become chief commercial officer. King release

> Industry association LifeSciences British Columbia has appointed Don Enns as the new president of the organization effective Sept. 7. LifeSciences BC release

> Easton Pharmaceuticals has announced that Lee Hendelson will join the company as CFO. Easton release

> AmStem has named Dwight Brunoehler as president of the company. AmStem release

> Inspire Pharmaceuticals has appointed Robert Savel, II, to the position of senior VP and chief technical officer, effective Sept. 20. Inspire release

> PPD has named Neil McCullough as VP of quality management systems. PPD release

> MethylGene has appointed Martin Godbout as chairman of the board of directors. MethylGene's board now numbers seven. MethylGene release

> XOMA has elected Jack Wyszomierski to its board of directors. Xoma release

> EUSA Pharma has appointed Stephen Stamp to the company's board as an independent non-executive director. EUSA release

> Flagship Biosciences has formed a scientific advisory board composed of experienced leaders in the pharmaceutical industry. The members are John Bloom, Joseph Krueger, David Eberhard, Hadi Yaziji, Holger Lange, Robert Dunstan, Lewis Kinter, Jens Nyengaard, Jerry Hardisty, Neal Goodwin and David Fairley. Flagship release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.